SFX by Ex Libris Inc.

Title:	EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations
Source:	Nature [0028-0836] McCabe, M T yr:2012

Basic

Full text

Full text available via Nature

Year:

Volume:

Issue:

Start Page:

Document delivery

Request document via Library/Bibliothek

Users interested in this article also expressed an interest in the following:
description	1.	Kuntz, R. "A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells." Nature chemical biology 8.11 (2012): 890-896.
description	2.	Kim, Kimberly H. "Targeting EZH2 in cancer." Nature Medicine 22.2 (2016): 128-34.
description	3.	Filippakopoulos, P. "Selective inhibition of BET bromodomains." Nature 468.7327 (2010): 1067-1073.
description	4.	HAYAKAWA, M. "Synthesis and biological evaluation of 4-morpholino-2-phenylquinazolines and related derivatives as novel PI3 kinase p110Î± inhibitors." Bioorganic & medicinal chemistry 14.20 (2006): 6847-5844.
description	5.	Tan, J. "Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells." Genes & development 21.9 (2007): 1050-63.
description	6.	Delmore, Jake E. "BET Bromodomain Inhibition as a Therapeutic Strategy to Target c - Myc." Cell 146.6 (2011): 2011-917.
description	7.	Garapaty Rao, S. "Identification of EZH2 and EZH1 Small Molecule Inhibitors with Selective Impact on Diffuse Large B Cell Lymphoma Cell Growth." Chemistry & biology 20.11 (2013): 1329-39.
description	8.	Cross, Nicholas C.P. C. "Aberrations ofEZH2in Cancer: Figure 1." Clinical Cancer Research 17.9 (2011): 2613-2618.
description	9.	Varambally, S. "The polycomb group protein EZH2 is involved in progression of prostate cancer." Nature 419.6907 (2002): 624-629.
description	10.	Bradley, Anthony R. "The SGC beyond structural genomics: redefining the role of 3D structures by coupling genomic stratification with fragment-based discovery." Essays Biochem 61.5 (2017): 495-503.
description	11.	Yap, Damian B. "Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation." Blood 117.8 (2011): 2451-2459.
description	12.	Zuber, J. "RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia." Nature 478.7370 (2011): 524-528.
description	13.	Daigle, Scott R. "Selective Killing of Mixed Lineage Leukemia Cells by a Potent Small-Molecule DOT1L Inhibitor." Cancer cell 20.1 (2011): 53-65.
description	14.	Yu, Z. "Ferroelectric-relaxor behavior of Ba(Ti0.7Zr0.3)O-3 ceramics." Journal of applied physics 92.5 (2002): 2655-2657.
description	15.	Chung, C. "Discovery and characterization of small molecule inhibitors of the BET family bromodomains." Journal of medicinal chemistry 54.11 (2011): 3827-3838.
description	16.	Nicodeme, E. "Suppression of inflammation by a synthetic histone mimic." Nature 468.7327 (2010): 1119-1123.
description	17.	Burkhardt, J.K. K. "The actin cytoskeleton in T cell activation." Annual review of immunology 26.1 (2008): 233-259.
description	18.	Pretzer, D. "Stability of the experimental anticancer agent [[(4-methoxyphenyl)sulfonyl]hydrazono]acetic acid (NSC-267213). II. Effect of structural modification on stability and mechanism of degradation." International Journal of Pharmaceutics 38.1 (1987): 161-169.
description	19.	Zheng, X. "Analgesic agents without gastric damage: Design and synthesis of structurally simple benzenesulfonanilide-type cyclooxygenase-1-selective inhibitors." Bioorganic & medicinal chemistry 15.2 (2007): 1014-1021.
description	20.	Gauuan, Polivina a. "Superoxide dismutase mimetics: synthesis and structure-activity relationship study of MnTBAP analogues." Bioorganic & medicinal chemistry 10.9 (2002): 3013-21.